Indigo
drugOn this page
Also known as Ao201C.I.73000Ci 73000Indigo blueIndigo wholeIndigofera orthocarpa wholeIndigofera tinctoriaIndigofera tinctoria wholeIndigotinNila wholeNili wholeNilika wholeNilini wholeNSC-8645True indigo whole1H,1'H-[2,2']Biindolylidene-3,3'-dioneSID26756710SID144205605SID170465746
Summary
Indigo (CHEMBL599552) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including acute promyelocytic leukemia and atopic eczema.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 6 conditions
- Chemistry: 262.26 Da · C16H10N2O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL599552 |
| Name | Indigo |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 10215 |
| Molecular formula | C16H10N2O2 |
| Molecular weight | 262.26 |
| InChIKey | QQILFGKZUJYXGS-UHFFFAOYSA-N |
SMILES: C1=CC=C2C(=C1)C(=C(N2)C3=NC4=CC=CC=C4C3=O)O
IUPAC name: 2-(3-hydroxy-1H-indol-2-yl)indol-3-one
Also known as: Ao201, C.I.73000, Ci 73000, Indigo, Indigo blue, Indigo whole, Indigofera orthocarpa whole, Indigofera tinctoria, Indigofera tinctoria whole, Indigotin, Nila whole, Nili whole
Patent coverage: 2,775 distinct patent families (6,024 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,005 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Inositol monophosphatase 1, Cyclin-dependent kinase 2/cyclin E1, Proto-oncogene tyrosine-protein kinase Src, Cyclin-dependent kinase 2, Aryl hydrocarbon receptor, Aldehyde dehydrogenase 1A1, Malate dehydrogenase, Chymotrypsinogen B.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| AHR | 8.3 | EC50 | 5 | nM | CHEMBL_ACT_25059582 |
| CCNE1 | 6 | IC50 | 1000 | nM | CHEMBL_ACT_16451853 |
| AHR | 5.77 | EC50 | 1700 | nM | CHEMBL_ACT_3112365 |
| ALDH1A1 | 5.5 | Potency | 3162 | nM | CHEMBL_ACT_4178175 |
| P97697 | 5.5 | Potency | 3162 | nM | CHEMBL_ACT_4407955 |
| TDP1 | 5.45 | Potency | 3548 | nM | CHEMBL_ACT_3929885 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| acute promyelocytic leukemia | 3 | MONDO:0012883 | EFO:0000224 |
| atopic eczema | 2 | MONDO:0004980 | EFO:0000274 |
| psoriasis | 2 | MONDO:0005083 | EFO:0000676 |
| anus neoplasm | 2 | MONDO:0003046 | EFO:0003835 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: acute promyelocytic leukemia